8 Things to Know About Fisetin as a Senolytic Supplement Being Studied for Menopause
When the research on senescent cells first started circulating in menopause spaces, it felt like one of those rare moments where a single biological mechanism suddenly explained so many things at once — the joint aches, the brain fog, the slow recovery. Fisetin isn't a magic fix, and anyone telling you otherwise is getting ahead of the evidence. But it's one of the more genuinely interesting areas of emerging research, and it deserves a clear-eyed look rather than either hype or dismissal.
Learn more about Rose →Senescent cells are a real and measurable problem in menopause — not a metaphor
Cellular senescence is a well-established biological process in which cells enter a state of permanent growth arrest after damage or stress, but critically, they don't clear themselves out the way they should. These lingering cells secrete a cocktail of inflammatory proteins collectively called the senescence-associated secretory phenotype (SASP), which disrupts neighboring healthy tissue. Estrogen normally helps regulate the clearance of senescent cells, so when estrogen falls during perimenopause, senescent cell burden measurably increases — a finding documented in human tissue studies, not just animal models.
Fisetin is a flavonoid with unusually strong senolytic activity compared to other plant compounds
Senolytics are compounds that selectively trigger apoptosis — programmed cell death — in senescent cells while leaving healthy cells largely unaffected. A landmark 2018 study published in EBioMedicine screened over a dozen natural compounds for senolytic potency and found fisetin to be the most effective, outperforming quercetin, curcumin, and resveratrol in reducing senescent cell markers in both mouse tissue and cultured human cells. Fisetin appears to work primarily by inhibiting pro-survival pathways that senescent cells depend on, particularly the PI3K/AKT signaling pathway.
The menopause-specific research is still in early stages — animal and small human trials only
As of 2024, the majority of fisetin research relevant to menopause has been conducted in ovariectomized mouse models, which mimic estrogen deficiency but are not a perfect proxy for the gradual hormonal shift of human perimenopause. The Mayo Clinic and other institutions have launched or completed Phase 1 and Phase 2 human trials examining senolytics (including fisetin) in conditions like frailty, osteoporosis, and diabetic kidney disease, but large randomized controlled trials specifically in menopausal women are not yet completed. Women considering fisetin should understand they are ahead of the conclusive evidence, not following it.
Bone density loss during menopause may be one of the most promising targets for fisetin research
Senescent osteocytes — aged bone cells — are strongly implicated in the accelerated bone loss that follows estrogen withdrawal, and mouse studies have shown that clearing senescent cells with senolytics including fisetin significantly reduces bone density loss and even partially restores bone microarchitecture. A 2017 study in Nature Medicine demonstrated that transplanting senescent cells into young mice caused bone loss that mirrored postmenopausal osteoporosis, and that senolytic treatment reversed much of this effect. Human trials targeting postmenopausal osteoporosis with senolytics are underway, though results are not yet published at scale.
Brain fog and cognitive symptoms may connect to neuroinflammation driven by senescent cells
Senescent cells accumulate in brain tissue as well as peripheral tissue, and the inflammatory signals they release — particularly interleukin-6 and TNF-alpha — are associated with neuroinflammatory states that impair memory consolidation and cognitive clarity. Fisetin has demonstrated the ability to cross the blood-brain barrier in animal studies, and research in aged mice has shown improvements in spatial memory and reduced neuroinflammatory markers following fisetin administration. Whether this translates meaningfully to the brain fog that many perimenopausal women experience remains to be confirmed in human trials, but the mechanistic pathway is coherent.
Dosing in research trials looks very different from typical supplement doses sold commercially
Human senolytic protocols studied at institutions like the Mayo Clinic typically use intermittent high-dose regimens — for example, fisetin at 20 mg per kilogram of body weight taken over two consecutive days, repeated monthly or less frequently — rather than a small daily maintenance dose. Most commercial fisetin supplements are sold in doses of 100–500 mg per day, which may not reach the threshold concentrations observed in research protocols and may not replicate the intermittent dosing pattern researchers believe is important for senolysis. Bioavailability is also a significant issue: fisetin is poorly absorbed without specific formulation strategies, meaning label dose and effective dose can differ substantially.
Fisetin also has antioxidant and anti-inflammatory properties independent of senolysis
Beyond clearing senescent cells, fisetin inhibits several pro-inflammatory enzymes including COX-2 and LOX, modulates NF-κB signaling (a central driver of systemic inflammation), and acts as a direct free radical scavenger. These properties exist separately from its senolytic mechanism and may contribute to symptom relief through different pathways — though they are also shared by many other flavonoids, making it harder to isolate fisetin's unique contribution in non-senolytic contexts. Women already consuming a varied diet rich in colorful fruits and vegetables are already receiving related flavonoids, though typically at much lower concentrations than studied therapeutically.
Fisetin is not a replacement for hormone therapy, and stacking them is unstudied territory
Hormone therapy directly addresses the estrogen withdrawal that triggers accelerated senescent cell accumulation in the first place — fisetin addresses downstream consequences of that accumulation, which is a fundamentally different intervention point. There are no published human studies examining whether fisetin and hormone therapy interact, complement each other, or interfere, and women using either should disclose both to their clinician. Fisetin is metabolized by CYP450 enzymes and theoretically could interact with medications processed through the same pathway, though clinical interaction data in humans remains sparse.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.